---
type: Condition
title: Treatment-Resistant Depression
description: Treatment-resistant depression (TRD) as addressed by CARMAhealth through advanced options — TMS therapy, Spravato (esketamine), and ketamine therapy.
resource: https://carmahealth.com/conditions/treatment-resistant-depression
tags: [carmahealth, condition, treatment-resistant-depression, trd, tms, esketamine, ketamine]
timestamp: 2026-07-08T20:00:00Z
---

# Treatment-Resistant Depression

Condition profile within the [CARMAhealth](../carmahealth.md) bundle. Facts below are drawn from the provider's own condition page, retrieved 2026-07-08.

## How CARMAhealth describes it

CARMAhealth defines treatment-resistant depression (TRD) as major depression that has not improved after adequate trials of at least two different antidepressant medications. The framing is that TRD is "not a dead end" — it does not mean the condition is untreatable, only that first-line approaches have not fit the patient's brain chemistry, and that newer treatments work through different brain pathways than traditional antidepressants. TRD is presented as the escalation path from the general [depression](./depression.md) profile.

## Screening / evaluation approach

A [psychiatric evaluation](../services/psychiatric-evaluation.md) reviews the full treatment history — medications tried, dosages, duration, and partial responses — and rules out other factors such as an incorrect initial diagnosis, medication interactions, or co-occurring conditions like [anxiety](./anxiety.md) or a thyroid disorder.

## Treatment options offered

- [TMS therapy](../services/tms-therapy.md) — FDA-cleared, non-invasive magnetic stimulation of mood-regulation brain regions; daily sessions over four to six weeks.
- [Spravato (esketamine)](../services/spravato.md) — FDA-approved nasal spray administered in-office, described as targeting NMDA glutamate receptors rather than serotonin or norepinephrine; administered twice weekly initially.
- [Ketamine therapy](../services/ketamine-therapy.md) — psychiatrist-supervised ketamine combined with structured therapeutic support; results described as often seen within one to six sessions.
- Medication augmentation or combination strategies via [medication management](../services/medication-management.md), per the site's FAQ.

## Claims noted (attributed)

- The site states, citing a review in World Psychiatry, that approximately 30 percent of individuals treated for major depressive disorder do not respond adequately to standard antidepressants — roughly 2.8 million U.S. adults — with an annual economic burden estimated at $43.8 billion.
- The site states, citing the Mayo Clinic, that treatment resistance reflects differences in brain chemistry, genetics, and co-occurring conditions, not personal failing.
- The site states TMS has been FDA-cleared for depression since 2008 and that clinical studies report response rates of 38 to 55 percent in TRD patients, with many patients noticing improvement within the first two to three weeks.
- The site states the FDA approved Spravato (esketamine) in 2019 as the first medication in decades to treat depression through a fundamentally new mechanism, with some patients reporting improvement within hours to days.
- The site states many insurers now cover TMS specifically for TRD (typically requiring documentation of prior medication trials) and that Spravato is covered by many insurers as an FDA-approved treatment.

## Sources

- Live page: https://carmahealth.com/conditions/treatment-resistant-depression — Retrieved 2026-07-08.
- Mirror: https://mr.carmahealth.com/conditions/treatment-resistant-depression — Retrieved 2026-07-08.